HOWL
vs
S&P 500
HOWL
S&P 500
Over the past 12 months, HOWL has underperformed S&P 500, delivering a return of -56% compared to the S&P 500's +14% growth.
Stocks Performance
HOWL vs S&P 500
Performance Gap
HOWL vs S&P 500
Performance By Year
HOWL vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Werewolf Therapeutics Inc
Glance View
Werewolf Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 39 full-time employees. The company went IPO on 2021-04-30. The firm is focused on developing a pipeline of cancer treatments. The company is developing immuno-stimulatory therapeutics designed to act selectively within the tumor microenvironment to enhance the body’s immune response to cancer. Its PREDATOR platform is designed to conditionally activate molecules that stimulate both adaptive and innate immunity while addressing the limitations of conventional proinflammatory immune therapies. The INDUKINETM molecules, are intended to selectively target the tumor microenvironment (TME). PREDATOR platform consists of protein engineering technologies which are used to generate INDUKINE molecules with multiple functional domains rationally engineered into a single protein to achieve the pharmaceutical profile. The firm using PREDATOR platform, has developed three initial product candidates: WTX-124, WTX-330 and WTX-613.